76544-6
LaboratoryBreast cancer 10-year risk of distant recurrence score Calculated by Prosigna
Definition
The 10-year breast cancer distant recurrence risk score (also referred to as ROR Score or Risk of Recurrence Score) is a numerical score on a scale of 0 -100 that is calculated using a statistical model that includes: 1) the results from a 50-gene expression assay performed on formalin fixed paraffin embedded breast tumor tissue previously diagnosed as invasive carcinoma; 2) proliferation score; and 3) gross tumor size. The calculated score and information about lymph node status are used together to classify the patient into a risk category for distant breast cancer recurrence at 10 years. This term was created for the Prosigna™ Breast Cancer Prognostic Gene Signature assay, which is intended for use in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer who have undergone surgery and are to be treated with adjuvant endocrine therapy alone.
LOINC 6-Axis Classification
Component
Breast cancer 10Y risk of distant recurrence score
Property
Score
Time Aspect
Pt
System
^Patient
Scale Type
Qn
Method Type
Calculated.Prosigna
Details
Class
MOLPATH
Order/Observation
Both
Short Name
Brst ca 10Y dist recur score Prosigna
Display Name
Breast cancer 10-year risk of distant recurrence score Calculated by Prosigna [Score]
Related Names
Frequently Asked Questions
What is LOINC code 76544-6?
LOINC code 76544-6 identifies "Breast cancer 10-year risk of distant recurrence score Calculated by Prosigna". The 10-year breast cancer distant recurrence risk score (also referred to as ROR Score or Risk of Recurrence Score) is a numerical score on a scale of 0 -100 that is calculated using a statistical model that includes: 1) the results from a 50-gene expression assay performed on formalin fixed paraffin embedded breast tumor tissue previously diagnosed as invasive carcinoma; 2) proliferation score; and 3) gross tumor size. The calculated score and information about lymph node status are used together to classify the patient into a risk category for distant breast cancer recurrence at 10 years. This term was created for the Prosigna™ Breast Cancer Prognostic Gene Signature assay, which is intended for use in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer who have undergone surgery and are to be treated with adjuvant endocrine therapy alone.
What does 76544-6 measure?
This code measures Breast cancer 10Y risk of distant recurrence score in ^Patient. It belongs to the MOLPATH class in the LOINC classification.
What is LOINC?
LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.